INTS Stock Analysis: Buy, Sell, or Hold?
INTS - Intensity Therapeutics, Inc. Common stock
$0.37
-0.01 (-2.53%)
▼
HOLD
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Mar 12, 2026
Get Alerted When INTS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
3 traders called INTS this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: INTS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: INTS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: INTS is currently trading at $0.37, which is considered oversold relative to its 30-day fair value range of $0.38 to $0.42.
Technical Outlook: Technically, INTS is in a downtrend. The price is currently testing key support at $0.36. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: INTS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $2.92 (+697.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, INTS is in a downtrend. The price is currently testing key support at $0.36. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: INTS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $2.92 (+697.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$0.38 -
$0.42
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
Protect Your Profits
Holding INTS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 697.8% below Wall St target ($2.92)
- CAUTION: 5-day price weakness (-7.7%) - monitor closely
Fair Price Analysis
30-Day Fair Range
$0.38 -
$0.42
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$0.36
Resistance Level
$0.44
Current Trend
Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-1.66
Wall Street Target
$2.92
(+697.8%)
Last updated: February 01, 2026 6:03 AM ET
Data refreshes hourly during market hours. Next update: 7:03 AM
Data refreshes hourly during market hours. Next update: 7:03 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INTS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 54 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$486 | 45 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$500 | 62 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$91 | 64 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$830 | 52 HOLD |
Advanced INTS Option Strategies
Professional options setups generated by AI based on today's INTS price and gamma walls.
